377 related articles for article (PubMed ID: 27192116)
1. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
[TBL] [Abstract][Full Text] [Related]
2. Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.
Sittig SP; van Beek JJP; Flórez-Grau G; Weiden J; Buschow SI; van der Net MC; van Slooten R; Verbeek MM; Geurtz PBH; Textor J; Figdor CG; de Vries IJM; Schreibelt G
Eur J Immunol; 2021 Jun; 51(6):1494-1504. PubMed ID: 33675038
[TBL] [Abstract][Full Text] [Related]
3. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.
Boasso A; Herbeuval JP; Hardy AW; Winkler C; Shearer GM
Blood; 2005 Feb; 105(4):1574-81. PubMed ID: 15466932
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.
Hwu P; Du MX; Lapointe R; Do M; Taylor MW; Young HA
J Immunol; 2000 Apr; 164(7):3596-9. PubMed ID: 10725715
[TBL] [Abstract][Full Text] [Related]
5. A peripheral blood mononuclear cell-based in vitro model: A tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1).
Gonçalves M; Furgiuele A; Rasini E; Legnaro M; Ferrari M; Luini A; Rodrigues-Santos P; Caramelo F; Marino F; Pereira FC; Cosentino M
Eur J Pharmacol; 2024 Apr; 968():176420. PubMed ID: 38367683
[TBL] [Abstract][Full Text] [Related]
6. Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia.
Xu SQ; Wang CY; Zhu XJ; Dong XY; Shi Y; Peng J; Qin P; Sun JZ; Guo C; Ni H; Hou M
Ann Hematol; 2012 Oct; 91(10):1623-31. PubMed ID: 22526360
[TBL] [Abstract][Full Text] [Related]
7. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
8. [GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro].
He SB; Sun K; Wang L; Li DC; Zhang YY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):410-4. PubMed ID: 20819479
[TBL] [Abstract][Full Text] [Related]
9. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response.
Trabanelli S; Lecciso M; Salvestrini V; Cavo M; Očadlíková D; Lemoli RM; Curti A
J Immunol Res; 2015; 2015():253191. PubMed ID: 25815345
[TBL] [Abstract][Full Text] [Related]
10. Tolerogenic Phenotype of IFN-γ-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine/AhR-IDO Loop.
Li Q; Harden JL; Anderson CD; Egilmez NK
J Immunol; 2016 Aug; 197(3):962-70. PubMed ID: 27316681
[TBL] [Abstract][Full Text] [Related]
11. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
[TBL] [Abstract][Full Text] [Related]
12. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
[TBL] [Abstract][Full Text] [Related]
13. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
Mellor AL; Chandler P; Baban B; Hansen AM; Marshall B; Pihkala J; Waldmann H; Cobbold S; Adams E; Munn DH
Int Immunol; 2004 Oct; 16(10):1391-401. PubMed ID: 15351783
[TBL] [Abstract][Full Text] [Related]
14. LPS enhances CTB-INSULIN induction of IDO1 and IL-10 synthesis in human dendritic cells.
Kim NS; Torrez T; Langridge W
Cell Immunol; 2019 Apr; 338():32-42. PubMed ID: 30910218
[TBL] [Abstract][Full Text] [Related]
15. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
16. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells.
Jürgens B; Hainz U; Fuchs D; Felzmann T; Heitger A
Blood; 2009 Oct; 114(15):3235-43. PubMed ID: 19625705
[TBL] [Abstract][Full Text] [Related]
17. Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.
Higashitani K; Kanto T; Kuroda S; Yoshio S; Matsubara T; Kakita N; Oze T; Miyazaki M; Sakakibara M; Hiramatsu N; Mita E; Imai Y; Kasahara A; Okuno A; Takikawa O; Hayashi N; Takehara T
J Gastroenterol; 2013 May; 48(5):660-70. PubMed ID: 22976933
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Regulatory T-Cell/Indoleamine 2,3-Dioxygenase Axis Reduces Vascular Inflammation and Atherosclerosis in Hyperlipidemic Mice.
Forteza MJ; Polyzos KA; Baumgartner R; Suur BE; Mussbacher M; Johansson DK; Hermansson A; Hansson GK; Ketelhuth DFJ
Front Immunol; 2018; 9():950. PubMed ID: 29867939
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.
Ou X; Cai S; Liu P; Zeng J; He Y; Wu X; Du J
J Cancer Res Clin Oncol; 2008 May; 134(5):525-33. PubMed ID: 17909857
[TBL] [Abstract][Full Text] [Related]
20. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
[Next] [New Search]
